Your browser doesn't support javascript.
loading
The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Alberts, Peteris; Tilgase, Andra; Rasa, Agnija; Bandere, Katrina; Venskus, Dite.
Affiliation
  • Alberts P; International Virotherapy Center, Teatra iela 9-9, Riga LV-1050, Latvia. Electronic address: peteris@virotherapy.eu.
  • Tilgase A; International Virotherapy Center, Teatra iela 9-9, Riga LV-1050, Latvia.
  • Rasa A; International Virotherapy Center, Teatra iela 9-9, Riga LV-1050, Latvia.
  • Bandere K; International Virotherapy Center, Teatra iela 9-9, Riga LV-1050, Latvia.
  • Venskus D; International Virotherapy Center, Teatra iela 9-9, Riga LV-1050, Latvia.
Eur J Pharmacol ; 837: 117-126, 2018 Oct 15.
Article in En | MEDLINE | ID: mdl-30179611
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oncolytic Virotherapy / Melanoma Type of study: Guideline / Observational_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Eur J Pharmacol Year: 2018 Document type: Article Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oncolytic Virotherapy / Melanoma Type of study: Guideline / Observational_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Eur J Pharmacol Year: 2018 Document type: Article Country of publication: Netherlands